NSG BioLabs, Singapore’s largest provider of biotech co-working laboratory and office space, has successfully concluded a $14.5 million financing round.

The round was led by Celadon Partners, an Asian private equity firm, with participation from ClavystBio, a life science investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas to health impact, NSG BioLabs said in a statement on Tuesday.

With these fresh funds, NSG BioLabs intends to enhance its product and services and to introduce additional facilities to meet the growing demands of biotech startups and multinational companies in Singapore and Southeast Asia.

NSG BioLabs has also announced its partnerships with Enterprise Singapore (EnterpriseSG), the Singapore government agency championing enterprise development, and Merck, a leading science and technology company, to bolster the biotech landscape by providing needed resources such as funding, expertise and networks to advance startup research and development (R&D).

NSG BioLabs said these achievements reaffirm its strength and expertise in providing high-quality, well-managed, and turnkey Biosafety Level 2 (BSL-2) certified laboratory and office spaces.

Moreover, it said these milestones underscore the firm as an ecosystem catalyst, providing value-add services and networks, which are important in driving scientific innovation and business growth.

“NSG BioLabs is committed to supporting innovators and proud to have helped in Singapore’s growing biotech ecosystem,

“Our partnerships with EnterpriseSG and Merck signify the importance of a collaborative spirit, and we hope to spur greater collaboration among other stakeholders to benefit the biotech industry in Singapore and the Asia Pacific region,” said Daphne Teo, Chief Executive Offier and Founder of NSG BioLabs.

“We look forward to further empowering our residents in their innovation efforts through expanded facilities, enhanced value-add offerings, and greater exposure to valuable industry networking and mentorship experiences,” she added.

Founded with a focus on supporting biotech innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of teams and global networks to assist life sciences companies.

Its conducive R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 35,000 square feet in the prime location of Biopolis in Singapore.

Since 2019, NSG BioLabs has been assisting innovators in creating impactful solutions in the health, biomedical, agrifood, and industrial biotechnology sectors, working in areas such as precision medicine, nucleic acids, artificial intelligence (AI)-enabled drug discovery, and synthetic biology.

With the largest co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks with partners, suppliers and industry experts, NSG BioLabs has helped over 40 companies as residents.

The company’s residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones.

The startup residents alone have successfully raised nearly $400 million in funding and supported hundreds of jobs.

“As the Southeast Asia biotech sector experiences tremendous growth driven by healthcare needs, we are confident that NSG BioLabs’ innovative co-working model can offer compelling solutions for biotech startups and companies across the region,

“NSG BioLabs’ dedication to empowering companies to fast-track their research and development efforts is commendable,” said Donald Tang, Managing Partner at Celadon Partners.

Khoo Shih, Chief Executive Officer at ClavystBio, said the firm is excited to foster the growth of Singapore’s life science ecosystem through our support of NSG BioLabs, and its resident startups.

“This investment reinforces ClavystBio’s mission to accelerate breakthrough science into health impact through venture building, and strategic partnerships,,” she added.

Since its inception, NSG BioLabs has been supporting biotech startups and multinational companies by providing BSL-2 certified private and shared laboratory spaces and offices, equipment, as well as, privileged access with service providers and suppliers, and community engagement.

After its first site opening in November 2019, NSG BioLabs expanded with its second site in August 2021, and recently 2023 with its third site.

Now, with three sites totaling 35,000 square feet, NSG BioLabs cements its space as a key hub for biotech innovation.

As one of the largest private biotech incubators in the region, coupled with its recent partnerships and strategic investors, NSG BioLabs said it is poised to enhance its value-add offerings of infrastructure, services, and networks to its growing community.

Singapore’s Beam sees revenue grow 36 percent on year in 2023